GeneToBe, Inc. is a biotechnology company based in Ann Arbor, Michigan, and a spinout of the University of Michigan. Our mission is to develop novel, lifelong therapies for patients with unmet medical needs. Currently, our Research and Development focuses on Cystic Fibrosis, Usher Syndrome, and Metabolic Dysfunction-associated Steatohepatitis. GeneToBe was founded by Dr. Charles Bisgaier, PhD, and Dr. Eugene Chen, MD, PhD, and is advancing cutting-edge platforms in genetic medicine. Our siRNA gene silencing technology is a precision medicine approach that targets genetically-defined patient populations, while our MiCas9 platform represents a next-generation CRISPR/Cas9 system that enables precise and efficient in vivo gene editing. At GeneToBe, we are committed to pushing the boundaries of genetic therapies, with the goal of transforming patient care and improving lives.